Toxicity Management and Monitoring Strategies

Dr. Arana Yi addresses common side effects beyond differentiation syndrome, including QT prolongation and cytopenias described in KOMET-001 and AUGMENT-101 clinical trials. She inquires about differences between ziftomenib and revumenib regarding QT prolongation and cytopenia management approaches. Dr. Patel acknowledges greater revumenib experience through University of Chicago trial participation, noting similar differentiation syndrome rates in NPM1-mutated disease for both agents when used as monotherapy, with potentially less QT prolongation signal with ziftomenib while cytopenias remain relatively similar, particularly thrombocytopenia.

QT prolongation management involves removing potential QT-prolonging medications before starting either ziftomenib or revumenib. Examples include switching from levofloxacin antibacterial prophylaxis to cefdinir, changing from posaconazole antifungal prophylaxis to itraconazole or voriconazole without similar QT issues when strong antifungal indications are absent. Electrolyte correction and frequent electrocardiogram monitoring during first cycles (at least weekly) with local physician partnerships enable appropriate monitoring. Additional QT-prolonging medication removal including ondansetron and olanzapine for nausea requires vigilance to maximize patient therapy continuation without dose interruptions.

Drug-drug interaction considerations include revumenib's interaction with posaconazole requiring significant dose adjustments, while ziftomenib should not be taken concurrently with acid-blocking agents due to efficacy impairment or toxicity increase potential. Dr. Arana Yi describes Mayo Clinic's ziftomenib experience with baseline electrocardiogram requirements and periodic monitoring during induction cycles weekly, then cycle beginnings subsequently. Cytopenia management involves close monitoring with treatment holds for grade 3 or higher cytopenias until improvement, then potential treatment resumption. Drug interaction prevention includes proton pump inhibitor medication review and alternative gastritis treatments to prevent absorption decrease or efficacy diminishment.